Viravan Rx-to-OTC switch?
This article was originally published in The Tan Sheet
PediaMed Pharmaceuticals is assessing OTC potential of its "switchable" products including its Viravan pediatric antihistamine/decongestant line, according to incoming President Cameron Durrant, MD. Durrant, whose appointment was announced Aug. 7, was VP-global business planning at Pharmacia and previously held senior positions in sales and marketing with GlaxoWellcome and Merck in the U.K. PediaMed grew from nine employees and revenue under $1 mil. in 2001 to around 75 employees and revenue in the "tens of millions" in FY 2003, according to Durrant. The new president says the firm's strengths lie in its healthy pipeline and drug delivery technology. Pediamed's only current OTC offering is Klout lice removal treatment...
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.